Public markets - biotech reverse merger and listing runway

Treeline Biosciences announced it will go public via a reverse merger with Standard BioTools, in an all-stock transaction valued around Standard BioTools’ net cash position plus additional value tied to pre-merger assets and earned payouts. The combined company will operate as Treeline Biosciences and trade on Nasdaq under ticker TRLN, with expected cash runway into 2029, while Standard BioTools plans to exit its mass cytometry and microfluidics businesses.